• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Basic Materials·EXCELINDUS.NS
Share

Excel Industries Limited Stocks

₹ 938.15Last Updated 21.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

₹ 117.38M

₹ 938.15
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1941 and headquartered in Mumbai, India, Excel Industries Limited conducts business both domestically and internationally, focusing on the production and sale of a diverse array of chemicals, pharmaceutical precursors, and ecological solutions. The company's chemical portfolio includes offerings for industrial, specialty, and mining sectors; vital agrochemical components; specific products like casscel; various phosphorus derivatives; biocides and phosphonates; along with essential polymer inputs and specialized monomers. In its environmental segment, Excel provides soil enhancers, organic pesticides, and other bio-based items. Additionally, it manufactures critical penultimate pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and veterinary APIs. The company also engages in financial ventures.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair val

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.07.2026 15:35

"Bulls Can Confidently Aim for $100 a Barrel": Brent Jumps Above $98

23.07.2026 14:57

BofA has placed its bets on recent market leaders following the sell-off. It is expecting a reversal.

23.07.2026 14:43

The yield on 10-year German government bonds reached a 15-year high

23.07.2026 13:00

No Longer a “Black Swan”: Analysts Are Once Again Discussing a Scenario of $150 Oil

23.07.2026 11:29

Nebius shares surged: Google has decided to lease more capacity. Who else stands to benefit?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026